瑞波西汀与氟西汀治疗老年抑郁症的对照研究  

Comparison Study of Reboxetine and Fluoxetine on Treatment of Senile Depression

作　　者：刘美兰[1] 张仲荣[1] 张增[1] 苏中华[1] 

机构地区：[1]济宁市精神病防治院,山东济宁272051

出　　处：《中国药师》2008年第7期774-776,共3页China Pharmacist

摘　　要：目的:比较瑞波西汀与氟西汀治疗老年抑郁症的疗效和安全性。方法:用瑞波西汀与氟西汀对144例老年抑郁症患者进行为期6周的随机对照试验,用汉密顿抑郁量表(HAMD)评定疗效,用不良反应量表(TESS)评定不良反应。结果:瑞波西汀与氟西汀治疗老年抑郁症的疗效相当(P>0.05),其显效率分别为72.3%和75%;瑞波西汀致口干、便秘、皮肤异样感等不良反应较氟西汀多,而恶心、呕吐、腹泻、嗜睡等不良反应较氟西汀少。结论:瑞波西汀治疗老年抑郁症具有良好的疗效和安全性。Objective： To compare the efficacy and safety of reboxetine and fluoxetine in the treatment of senile depression. Method： One hundred and fourty-four patients were randomly assigned to receive reboxetine （ n = 72 ） and fluoxetine （ n = 72 ） for 6 weeks. Their efficacy were evaluated by Hamilton Depressine Scale （HAMD） and their adverse reactions were evaluated by the Treatment Emergent Symptom Scale（TESS）. Result： The efficacy of reboxetine and fluoxetine were nearly equal. The effective rates of reboxetine and fluoxetine was 72.3% and 75%, respectively. The ADR rates of dry mouth, constipation, abnormal skin perception of rebxefine were higher significantly than that in fluoxetine, but nausea, vomiting, diarrhea, somnolence were lower than that in fluoxetine. Conclusion： Reboxetine has good efficacy and safety in treating senile depression.

关 键 词：瑞波西汀 氟西汀 老年抑郁症 

分 类 号：R971.43[医药卫生—药品]